Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
Purpose
This single-center, prospective, randomized study will evaluate the safety and feasibility of Intracardiac echocardiography (ICE)-guided Left atrial appendage closure (LAAC) when compared to the traditional Transesophageal echocardiography (TEE) approach.
Condition
- Left Atrial Appendage Closure
Eligibility
- Eligible Ages
- Between 18 Years and 90 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Patients diagnosed for non-valvular atrial fibrillation with documented paroxysmal, persistent, or permanent NVAF. 2. Deemed to be at high risk of stroke or systemic embolism (SE) defined as a CHADS2 score ≥2 or a CHA2DS2-VASc score ≥3. 3. Patient suitable for OAC with warfarin or DOAC and have appropriate rationale to seek a nonpharmacologic alternative to long-term OAC, meeting commercial LAAO criteria indications. 4. Can undergo appropriate pre-procedural imaging with Computed tomography (CT) or transesophageal echocardiography (TEE). 5. Patient should be able to comply with the protocol. 6. Provide written informed consent before study participation. 7. Ages 18 and above
Exclusion Criteria
- ) A patient will be ineligible for inclusion in this study if he or she meets any of the following criteria: 1. Presence of an intracardiac thrombus on the preprocedural TEE or CT. 2. History of previously implanted device for atrial septal defect or patent foramen ovale. 3. Severe LV dysfunction (LVEF < 40%) or greater than moderate valvular heart disease. 4. Enrollment in another study that competes or interferes with this study. Approval to dual enroll must be approved by the other study. 5. Poor clinical condition like cardiogenic shock, which prohibits pre- and post-procedural function tests. 6. Subject with planned cardiac intervention between the time of consenting and up to 60 days post-LAAO. 7. Any other condition or co-morbidity which, in the opinion of the investigator or operator, may pose a significant hazard to the subject if he or she is enrolled in the study. 8. For women of childbearing potential: Pregnant or breastfeeding women or planning pregnancy during the course of the investigation are excluded due to the risks involved in the procedure 9. Children below 18 years, prisoners and patients who are unable to provide consent are excluded.
Study Design
- Phase
- N/A
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- Prospective, randomized, parallel controlled, open-label, single center study
- Primary Purpose
- Other
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator Intracardiac echocardiography Left atrial appendage closure. |
Intra cardiac echocardiography will be performed prior to left atrial appendage closure. |
|
|
Placebo Comparator Traditional transesophageal echocardiography guided Left atrial appendage closure |
Transesophageal Echocardiography will be performed under general anesthesia. |
|
Recruiting Locations
Plano, Texas 75093
More Details
- Status
- Recruiting
- Sponsor
- Baylor Research Institute
Detailed Description
The primary objective of this study is to assess the efficacy and safety of using Intracardiac echocardiography (ICE) to guide implantation of percutaneous left atrial appendage closure (LAAC) devices. Primary endpoints include procedural success following implantation of the left atrial appendage occlusion (LAAO) device. Procedural success specifies that the device should be implanted in the correct position without device related complications and no peri-device leaks >5 mm on color doppler. Secondary end points include periprocedural complications (such as pericardial effusion/tamponade, stroke, death, vascular complications, and device embolization), procedural characteristics (total duration, fluoroscopy time, contrast volume, Length of hospital stay), cost of hospitalization, in-hospital patient satisfaction, and clinical alterations at 45-day follow-up.